Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia

Chinese Medical Journal

Volumn 126, Issue 21, 2013, Pages 4145-4148

  Cui, Zhong Guang ^a,b   Liu, Xin Guang ^a   Qin, Ping ^a   Hou, Ming ^a   Wu, Shao Ling ^b   Peng, Jun ^a   Zhao, Hong Guo ^b   Wang, Hong Yi ^b   Zhao, Chun Ting ^b  

^a SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Cyclosporin A; Immune thrombocytopenia; Recombinant human thrombopoietin

Indexed keywords

CYCLOSPORIN A; RECOMBINANT THROMBOPOIETIN;

ABDOMINAL DISTENSION; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL OBSERVATION; CONTROLLED STUDY; CORTICOSTEROID RESISTANT PRIMARY IMMUNE THROMBOCYTOPENIA; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MALE; MEDICAL RECORD REVIEW; NAUSEA; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; CYCLOSPORINE; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOPOIETIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887113977     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20131116     Document Type: Article

References (19)

1. Johnsen J. Pathogenesis in immune thrombocytopenia: new insights. Hematology Am Soc Hematol Educ Program 2012; 2012: 306-312
2. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children, report from an international working group. Blood 2009; 113: 2386-2393
3. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006; 4: 2377-2383
4. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186
5. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207
6. Zhao YQ, Wang QY, Zhai M, Xu J, Chen XQ, Liu WL, et al. A multi-center clinical trial of recombinant human thrombopoietin in chronic refractory idiopathic thrombocytopenic purpura. Chin J Intern Med (Chin) 2004; 43: 608-610
7. Liu XG, Peng J, Hou M. Restoration of T cell tolerance in primary ITP. J Hematol Oncol 2012; 5 Suppl 1: A5
8. Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004; 103: 2645-2647
9. Olsson B, Andersson PO, Jacobsson S, Carlsson L, Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005; 93: 139-144
10. Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78: 139-143
11. Olsson B, Andersson PO, Jernås M, Jacobsson S, Carlsson B, Carlsson LM, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124
12. Hou M, Andersson PO, Stockelberg D, Mellqvist UH, Ridell B, Wadenvik H. Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br J Haematol 1998; 10: 420-424
13. Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010; 115: 2755-2762
14. Guo L, Dong XY, Li J. Recombinant Human Thrombopoietin (rh-TPO) in Combination with Rituximab As a Novel Therapy in Corticosteroid-Resistant Primary Immune Thrombocytopenia (ITP). ASH Annual Meeting Abstracts 2011; 118: 2223
15. Wang S, Yang R, Zou P, Hou M, Wu D, Shen Z, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol 2012; 96: 222-228
16. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 2002; 114: 433-437
17. Peng J, Liu C, Liu D, Ren C, Li W, Wang Z, et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura. Blood 2003; 101: 2721-2726
18. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 2001; 114: 121-125
19. Emilia G, Luppi M, Morselli M, Forghieri F, Potenza L, Torelli G. A possible role for low-dose cyclosporine in refractory immune thrombocytopenic purpura. Haematologica 2008; 93: 1113-1115. (Received April 26, 2013)